Department of Pharmacology, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Department of Health Protection & Communicable Diseases Control, Ministry of Public Health, Doha, Qatar.
Front Immunol. 2021 Feb 26;12:631139. doi: 10.3389/fimmu.2021.631139. eCollection 2021.
COVID-19 emerged from China in December 2019 and during 2020 spread to every continent including Antarctica. The coronavirus, SARS-CoV-2, has been identified as the causative pathogen, and its spread has stretched the capacities of healthcare systems and negatively affected the global economy. This review provides an update on the virus, including the genome, the risks associated with the emergence of variants, mode of transmission, immune response, COVID-19 in children and the elderly, and advances made to contain, prevent and manage the disease. Although our knowledge of the mechanics of virus transmission and the immune response has been substantially demystified, concerns over reinfection, susceptibility of the elderly and whether asymptomatic children promote transmission remain unanswered. There are also uncertainties about the pathophysiology of COVID-19 and why there are variations in clinical presentations and why some patients suffer from long lasting symptoms-"." To date, there are no significantly effective curative drugs for COVID-19, especially after failure of hydroxychloroquine trials to produce positive results. The RNA polymerase inhibitor, remdesivir, facilitates recovery of severely infected cases but, unlike the anti-inflammatory drug, dexamethasone, does not reduce mortality. However, vaccine development witnessed substantial progress with several being approved in countries around the globe.
COVID-19 于 2019 年 12 月在中国出现,2020 年已传播至包括南极洲在内的各大洲。冠状病毒 SARS-CoV-2 已被确定为病原体,其传播已超出了医疗体系的承受能力,并对全球经济产生了负面影响。本综述提供了有关该病毒的最新信息,包括基因组、变异出现的风险、传播方式、免疫反应、儿童和老年人的 COVID-19 以及为控制、预防和管理该疾病而取得的进展。尽管我们对病毒传播机制和免疫反应的了解已经大大得到了澄清,但对再次感染、老年人易感性以及无症状儿童是否促进传播的担忧仍然没有得到解答。关于 COVID-19 的病理生理学以及为什么临床表现存在差异,以及为什么有些患者会出现长期症状的问题,目前仍存在不确定性。到目前为止,针对 COVID-19 还没有非常有效的治疗药物,特别是羟氯喹试验未能产生阳性结果之后。RNA 聚合酶抑制剂瑞德西韦有助于严重感染病例的康复,但与抗炎药地塞米松不同,它不能降低死亡率。然而,疫苗的开发取得了重大进展,全球多个国家已批准了多种疫苗。